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ABSTRACT 
 Heart Failure is now considered as one of the leading cause for mortality and 
morbidity. It is affecting several organs and cause organ damages due to the myocardial 
failure to pump inadequate oxygenated blood to the body including metabolites, to end 
organs and peripheral tissues.  Heart failure results from multifactorial mechanism 
including neurohumoral activations including increased activity of the sympathetic 
nervous system, renin-angiotensin aldosteron system, vasopression and the atrial 
natriuretic peptide. This neurohumoral pathway has significant contribution to the 
development of myocardial dysfunction that lead to clinical manifestation of heart failure. 
Some of the markers in these pathways have now been considered as an independent 
predictors of prognosis in heart failure patient.  
 
Introduction 
 Heart failure is a syndrome that 
currently being understood as a 
systemic failure that result in decrease 
oxygen perfusion due to dysfunction of 
myocardium in performing good 
contractility. The worldwide incidence 
of heart failure has increased to 26 
millions, and 74% of the cases cause 
one comorbidity that worsens patient 
health status. In Asia, the prevalence 
is ranging from 1-5% and overall 
prevalence is estimated to be 4.2 
million in China and 1.3-4.6 million in 
India1,2.  
 The failure of ventricular 
function causes inability of the heart to 
deliver adequate blood to the body to 
meet end-organ metabolic demands 
and oxygenation at rest or during mild 
exercise will further result in organ 
damages. The failing heart strives to 
balance “preload” and “afterload” for 
compensation of impaired contractility 
and to deter the development of 
congestion, which occur via several 
interdependence mechanisms. 
Regulation of circulating blood volume 
in physiological condition is controlled 
to maintain the cardiovascular 
homeostasis. The damage in structure 
and function of the myocardium lead to 
changes in these regulations and 
result in compensatory mechanism 
that is regulated through the activation 
of neurohumoral and autonomic 
nervous system. The disruption in 
receptor activation cause imbalance in 
the autonomic system with increased 
sympathetic activity and diminished 
vagal reflexes, both of which may have 
profound effects on cardiac function 
and structured. Furthermore, the 
decreased ventricular function and 
activation of the SNS will cause low 
blood perfusion to the kidney and 
stimulates the activation of renal 
aldosterone angiotensin system and 
vasopressin release3,4. The activation 
in these complex neurohumoral 
mechanisms support and maintain 
tissue organ perfusion. The schematic 
neurohumoral adaptation in heart 
failure is shown in figure 1 and the 
processes by which depressed 
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myocardium may lead to systemic 
decompensation are shown in the 
figure 2. 
  
 
 
Figure 1. The activation of SNS and Neurohumoral system in the failing heart (reproduced from Hartupee 
J and Mann DL, 2017) 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2. The process of heart failure leads to end stage organ dysfunction 
 
Activation of sympathetic 
nervous system pathways 
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parasympathetic nervous system is 
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body changes, the baroreceptor in the 
aortic arch and carotid sinus, as well 
as mechanoreceptors at the 
cardiorespiratory system senses 
arterial wall tension and produce 
signals3. These signals cause increase 
in sympathetic impulse through 
norepinephrine or parasympathetic 
one via acetylcholine. At the peripheral 
vessels, the chemoreceptors and 
metabolic receptors in the muscles will 
sense acid-base balance and 
oxygenation of the blood and further 
produce stimulation in the sympathetic 
impulse. The changes in mechanical 
and biochemical condition like 
hypoxia, hypotension or acid-base 
imbalance will be transmitted and 
sensed by those baroreceptors 
creating a feedback mechanism to 
maintain the cardiovascular 
homeostasis3.   
 During the early course of 
heart failure, the activation of the 
Sympathetic Nervous System (SNS) is 
one of the most important adaptations 
that occur in the very early stage. The 
failing ventricular function leads to 
increase in SNS signaling with 
subsequent release and reduce 
uptake in adrenergic neurotransmitter 
Norepinephine (NE) by the nerve 
endings, causing increased in 
circulating level of this 
neurotransmitter. In response, the 
parasympathetic receptor activity 
become dysfunctional by these 
sympathetic simulation, which in turn 
lead to increase in systemic vascular 
resistance and heart rate3. 
 
The renin-angiotensin-
aldosteron system (RAAS) 
pathways  
 The renin angiotensin aldos-
terone system functions as a controller 
in intravascula volume and resistance. 
During physiological condition, the 
RAAS is main hormonal signaling 
cascade to maintain body fluid and 
blood pressure homeostasis5. RAS 
influences BP by regulating sald and 
water balance and vasoconstriction. In 
addition, in the in vitro and in vivo 
model, the RAAS has plaucible 
function in the cellular and tissue 
remodeling as well as the increase 
response in inflamatory process. Thus, 
the inapporpriate response of the 
RAAS during certain pathological 
condition will lead to tissue remodeling 
and dysfunction in cardiovascular 
system6.  
 In heart failure syndrome, the 
failed contractility of the ventricel 
causes renal hypoperfusion and 
together with sympathetic activity, the 
RAAS is activated in the later stage 
aafter SNS activation. This system is 
very sensitive and is activated with the 
extrication of renin from 
juxtaglomerular apparatus. Renin is 
first secreted, and it is a hormone that 
mediates the conversion of 
angiotensin I ro angiotensine II by 
angiotensin-converting enzyme (ACE). 
Reports showed that during heart 
failure, the activity of ACE is increased 
as shown that the tissue expression 
increased in the myocardium. This 
further supported with the increased in 
Angiotensin II activity during heart 
failure that stimulates vasoconstriction, 
cellular growth and tissue remodeling, 
extracellular matrix synthesis which 
may exacerbate the fibrosis in heart 
failure condition3,6. There are two 
opposing receptors that binds to 
Angiotensin II and mediates its activity, 
Angiotensin recepor type 1 and 
Angiotensin receptor type 2. The 
activation of type 1 receptor leads to 
cell growth, vasoconstriction and 
mediates fibrotic process. The 
activation of type 2 receptors leads to 
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the inhibition of cell growth and 
vasodilatation. Indeed, the effects of 
Angiotensin II on cardiovascular, renal, 
and cerebral functions are mediated 
through the activation of angiotensin 
type 1 (AT1) receptors, but these 
actions are counteracted by activation 
of the AT2 receptor3. Aldosterone has 
similar actions with unfavorable effects 
of angiotensin II. Aldosterone 
provokes hypertrophy and fibrosis 
within the vasculature and 
myocardium, resulting in ventricular 
stiffness, endothelial cell and 
baroreceptor dysfunction, and the 
inhibition of norepinephrine uptake6.  
 
Vasopressin  
 The arginin vasopressin 
system plays role in the mechanism of 
heart failure through its action in 
mediating the water clearance in the 
kidney. The release of vasopressin is 
provoked by Angiotensin II after it 
stimulates the thirst center in the brain. 
Normally in the setting of increased 
osmolality AVP is released resulting in 
increased water retention, which 
returns osmolality to its normal 
physiological set point. However, AVP 
levels are inappropriately elevated in 
many patients with heart failure3.  
 
The natriuretic peptide  
 Recently, the natriuretic 
peptide hormon has been reported to 
play its role in the compensatory 
mechanism of heart failure. Previously, 
Brain Natriuretic Peptide (BNP) has 
been widely reported and been used 
as a biomarker for heart failure. It has 
prognostic value in patients with post 
myocardial infarction and associated 
with decreased survival in those with 
reduced LVEF. The Natriuretic Peptide 
(NP) is a cardiac hormone reported 
being released in myocardium and the 
endothelium, with pleiotropic 
cardiovascular and metabolic 
properties. The wall stress due to 
volume overload or pressure overload 
during heart failure induces synthesis 
of natriuretic peptide, thus there is 
increased secretion of NP to 
counterbalance the increase effect of 
renin-angiotensin-aldosterone 
system7,8.  
 The release of NP in heart 
failure will induces vasodilation, 
natriuresis, and supress the RAAS. In 
the kidney, this hormone increases 
glomerular filtration rate by increasing 
afferent arteriolar dilation in addition to 
efferent arteriolar constriction, while in 
the different level of the nephron ANP 
inhibits water and sodium 
reabsorption. Moreover, NPs has 
effect on antagonizing cardiac 
hypertrophy and fibrosis leading to 
myocardial remodeling in heart failure. 
The complete pleiotropic effect is 
shown in figure 39. The clearance of 
NPs is mediated through a specific 
natriuretic peptide degrading receptor 
called NPR-C that binds the NPs and 
through a mechanism of endocytosis it 
degraged and forms an inactive 
molecule (Figure 4)8. A breakthrough 
discovery in fdrug development 
recently has targeted the inhibition of 
NPs as one mechanism in the 
treatment approach of heart failure10.  
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Figure 3. Effects of the natriuretic peptide system: cardiovascular and renal effects of NP system 
counteract the action of RAAS 
 
 
 
Figure 4. Natriuretic peptides signaling and the degradation and clearance 
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